Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylphenidate (Janssen Pharmaceutical)
- Development stage
- Approved
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Methylphenidate-OROS, marketed under the brand name Concerta, is an extended-release formulation of the central nervous system (CNS) stimulant methylphenidate. It utilizes the Osmotic-controlled Release Oral delivery System (OROS) technology to provide a steady release of the medication over a 12-hour period. The system consists of an immediate-release overcoat (22% of the dose) followed by a gradual osmotic pump-driven release of the remaining 78%. It is primarily indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults. Its mechanism of action involves the inhibition of dopamine and norepinephrine transporters, thereby increasing the synaptic concentrations of these neurotransmitters in the prefrontal cortex and basal ganglia.
- Brand names
- Concerta
- Other names
- methylphenidate-OROSOROS methylphenidatemethylphenidate hydrochloride extended-release
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on methylphenidate (Janssen Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylphenidate (Janssen Pharmaceutical).